Capital Fund Management S.A. Boosts Position in United Therapeutics Co. (UTHR)

Capital Fund Management S.A. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 101.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 124,012 shares of the biotechnology company’s stock after purchasing an additional 62,524 shares during the period. Capital Fund Management S.A.’s holdings in United Therapeutics were worth $18,348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of UTHR. Wedge Capital Management L L P NC lifted its position in United Therapeutics by 2,725.8% during the fourth quarter. Wedge Capital Management L L P NC now owns 324,631 shares of the biotechnology company’s stock valued at $48,029,000 after purchasing an additional 313,143 shares during the period. Old Mutual Global Investors UK Ltd. lifted its position in United Therapeutics by 30.3% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 970,846 shares of the biotechnology company’s stock valued at $113,773,000 after purchasing an additional 225,953 shares during the period. JPMorgan Chase & Co. lifted its position in United Therapeutics by 28.0% during the third quarter. JPMorgan Chase & Co. now owns 640,475 shares of the biotechnology company’s stock valued at $76,065,000 after purchasing an additional 139,976 shares during the period. APG Asset Management N.V. lifted its position in United Therapeutics by 24.5% during the third quarter. APG Asset Management N.V. now owns 652,000 shares of the biotechnology company’s stock valued at $76,408,000 after purchasing an additional 128,404 shares during the period. Finally, LSV Asset Management lifted its position in United Therapeutics by 59.8% during the fourth quarter. LSV Asset Management now owns 274,146 shares of the biotechnology company’s stock valued at $40,559,000 after purchasing an additional 102,565 shares during the period.

A number of brokerages have weighed in on UTHR. ValuEngine downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Credit Suisse Group reiterated an “underperform” rating and issued a $118.00 price objective on shares of United Therapeutics in a research report on Thursday, January 18th. BidaskClub downgraded shares of United Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a research report on Monday, January 15th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research report on Friday, January 5th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $140.27.

United Therapeutics Co. (NASDAQ:UTHR) opened at $136.92 on Thursday. The firm has a market cap of $5,581.57, a PE ratio of 11.39 and a beta of 1.26. United Therapeutics Co. has a 1 year low of $112.01 and a 1 year high of $169.89.

In other news, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $134.72, for a total transaction of $78,137.60. Following the sale, the director now directly owns 1,555 shares of the company’s stock, valued at approximately $209,489.60. The disclosure for this sale can be found here. Insiders have sold 3,075 shares of company stock valued at $393,760 in the last three months. Corporate insiders own 7.80% of the company’s stock.

WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.themarketsdaily.com/2018/02/15/capital-fund-management-s-a-boosts-position-in-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply